All Posts Tagged With: "TMO"
(MDT) MedTech Industry Stock Outlook – March 2012 – Zacks Analyst Interviews
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(MDT) MedTech Industry Stock Outlook – March 2012 – Industry Outlook
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(STJ) New Year Bets from MedTech
Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean.
The U.S. economy continues to be cramped by a spate of headwinds including a still...
(TMO) Thermo Fisher Scientific Shares Maintained at Neutral
Recently, we reiterated our Neutral recommendation on Thermo Fisher Scientific (TMO) with a target price of $47.00.
Thermo Fisher continues to be focused on effectively deploying its cash balance to...
(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook
June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected...
(BA) Company News for July 28, 2011 – Corporate Summary
• Boeing (NYSE:BA) reported Q2 EPS of $1.25, beating the Zacks Consensus Estimate of $0.97 per share. Revenues for the quarter rose 6.2% year-over-year to $ 16.5 billion
28Jul2011 | vitalstocks | 0 comments | Continued(PKI) PerkinElmer Analyst Upgrades Shares to Outperform
We upgrade our rating on PerkinElmer (PKI) to Outperform based on solid results and benefits accruing from extensive reorganization. First-quarter 2011 earnings per share of 34 cents surpassed the Zacks Consensus...
(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook
A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of...
(PKI) PerkinElmer Presents Corporate Social Responsibility Report
A global leader in human and environmental health, PerkinElmer (PKI) recently released its Corporate Social Responsibility (“CSR”) Report for 2010. This report provides information on the company’s achievements...
(VIVO) FDA OKs Meridian C. Difficile Test
Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier...
(AFFX) Affymetrix Analyst Initiates Shares at Neutral
We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus...
(DGX) Quest Diagnostics Expedites Celera Acquisition
Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The...
(AAPL) Company News For December 13, 2010 – Corporate Summary
• Thermo Fisher (NYSE:TMO) said it would purchase Dionex (NASDAQ:DNEX), a manufacturer of chemical analysis equipment, for $118.50 per share, or $2.1 billion
• According...
(WAT) Waters Corporation Earnings Slightly Below The Street
Waters Corp. (WAT) released its third quarter earnings before the market opened today, reporting earnings from continuing operation of 96 cents, slightly below the Zacks Consensus Estimate of 97 cents. Earnings...
(WAT) Waters Corporation Third Quarter 2010 Earnings Preview
Waters Corp. (WAT) is slated to report its third quarter 2010 earnings on October 26, 2010 before the opening bell. The current Zacks Consensus Estimate for the third quarter is 97 cents per share, representing...
(PKI) PerkinElmer Signs to Aquire Signature Genomic Laboratories
PerkinElmer Inc. (PKI) announced recently that it has agreed to acquire Signature Genomic Laboratories LLC, a diagnostic genetic testing company. The transaction is expected to close in May 2010.
As...
(TMO) Thermo Fisher Scientific Announces Aquisition of Proxeon
Thermo Fisher Scientific Inc. (TMO) announced that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis. Financial terms of the transaction have not been disclosed.
Thermo...
(TMO) Thermo Fisher Scientific Analyst Remains Neutral
We have retained our ‘Neutral’ rating on Thermo Fisher Scientific, Inc. (TMO) with a target price of $55 based on a P/E of 16.2 and our fiscal 2010 EPS estimate of $3.39. The company’s results for the...
(TMO) Thermo Fisher Scientific Expands Agreement with Eli Lilly
Thermo Fisher Scientific Inc. (TMO) recently expanded its clinical trial materials supply chain relationship agreement with Eli Lilly and Company (
29Mar2010 | vitalstocks | 0 comments | Continued(TMO) Thermo Fisher Scientific Acquires Finnzymes
Thermo Fisher Scientific, Inc. (TMO) recently completed the acquisition of Finnzymes. Financial terms of the agreement have not been disclosed. The acquisition is not expected to have any material impact on...
(TMO) Thermo Fisher Scientific Acquires Ahura
Thermo Fisher Scientific, Inc. (TMO) recently completed the acquisition of Ahura Scientific for $145 million in cash plus the potential for an earn-out payment based on the achievement of certain 2010 financial...
(TMO) Thermo Fisher Scientific Surpasses Analyst Estimates
Thermo Fisher Scientific, Inc. (TMO) reported fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were 91 cents, surpassing the Zacks Consensus Estimate of 88 cents and...
(TMO) Thermo Fisher Scientific to Acquire Finnzymes
Thermo Fisher Scientific Inc. (TMO) has recently signed an agreement to acquire Finnzymes, a provider of integrated tools for molecular biology analysis Incorporatedluding reagents, instruments, consumables...
(TMO) Thermo Fisher Scientific Analysts Initiate Coverage at Neutral
We recently initiated coverage on Thermo Fisher Scientific, Inc. (TMO) with a Neutral recommendation. We rate the stock as Neutral with a target price of $50 based on a P/E of 15.0x our fiscal 2010 EPS estimate...
(TMO) Thermo Fisher Scientific Earns New National Institutes of Health Contract
Thermo Fisher Scientific Inc. (TMO) recently received a new contract from the consortium of U.S. National Institutes of Health, Centers for Disease Control and Prevention and the Environmental Protection Agency....
(TMO) Thermo Fisher Scientific to Sell $350 Million in Notes
Thermo Fisher Scientific Inc. (TMO) decided to sell senior notes for refinancing certain of its outstanding indebtedness....
(WAT) Waters Corporation Modestly Outperforms
Waters Corporation (WAT) reported third quarter 2009 revenues of $374 million, a decrease of 3% over that of $386 million in the third quarter of 2008. On a GAAP basis, earnings...
(TMO) Thermo Fisher Scientific Meets Expectations
Thermo Fisher Scientific Inc. (TMO) today reported financial results for the third quarter of fiscal 2009. Earnings per share came in at 78 cents, exceeding both the Zacks Consensus Estimate and the year-ago...
(TMO) Thermo Fisher Scientific Issues Public Notice on Debenture Conversion
Thermo Fisher Scientific Inc. (TMO) recently began the process of issuing public notice to the holders of Floating Rate Convertible Senior Debentures of Apogent Technologies Inc. that are due in 2033, reminding them of their rights to convert the debentures....